🕒 Last update: loading…17/09/2026

Stock Organon & Co. OGN

Organon & Co. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 17/09/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2021 → 2022: -8.28%

Price change 2022 → 2023: -48.37%

Price change 2023 → 2024: 3.47%

Price change 2024 → 2025: -51.94%

Price change 2025 → 2026: 88.98%

Price change 2026 (year to date): 87.15%

Financial growth

Revenue CAGR (8 years): -6.27%

Earnings CAGR (8 years): -29.47%

Growth status: weak or negative trend (<1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 11.70

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 4.10

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.07% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Organon & Co.4.211.70−6.3 %🔒
AbCellera Biologics Inc.–0.15+35.8 %–
Tecan Group AG–0.19+6.0 %–
Carl Zeiss Meditec AG23.10.29+8.3 %–
Fielmann AG13.80.90+6.2 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Organon & Co. over the latest fiscal years.

Revenue
6.2 bn USD
fiscal year 2025
Net income
187 m USD
fiscal year 2025
Net margin
3.0 %
fiscal year 2025
Average annual growth
-1.0 %
Revenue growth over 5 years
Market cap
3.7 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20206.5 bn2.2 bn33.1 %n/a
20216.3 bn1.4 bn21.4 %-3.5 %
20226.2 bn917 m14.8 %-2.1 %
20236.3 bn1.0 bn16.3 %+1.4 %
20246.4 bn864 m13.5 %+2.2 %
20256.2 bn187 m3.0 %-2.9 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Valuation and competitors

Organon & Co. compared with its sector on the same exchange and with its main competitors.

Company P/E
4.2
85.0 % below the sector
Sector median P/E
27.7
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Organon & Co.3.7 bn4.23.0 %
Phibro Animal Health Corporation PAHC1.5 bn12.33.7 %
Aurinia Pharmaceuticals Inc. AUPH2.1 bn15.4101.5 %
Nuvation Bio Inc. NUVB1.4 bnn/a-325.3 %
Tilray Brands, Inc. TLRY272 mn/a-266.2 %
Harmony Biosciences Holdings, Inc. HRMY2.0 bn11.018.3 %
Pediatrix Medical Group, Inc. MD2.4 bn14.08.6 %
Guardian Pharmacy Services, Inc. GRDN3.1 bn43.43.4 %
Sector median (NYSE)27.7

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Organon & Co. publish: ratings, price targets and earnings forecasts.

Majority rating
hold
9 analysts

Breakdown of ratings

strong buy 0buy 2hold 4sell 3strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Organon & Co.

Free float
99.4 %
share of freely traded shares
Large funds tracked
22
hold the stock as of 2026Q2
Executives (insiders)
0 / 1
0 purchases, 1 sales in 130 days
US elected officials
3
0 purchases, 3 sales in 12 months

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
BlackRock32.1 m434 m0.0 %+1.1 %2026Q2
Vanguard Group36.9 m265 m0.0 %+2.7 %2025Q4
State Street19.3 m262 m0.0 %+94.0 %2026Q2
Goldman Sachs5.2 m70.4 m0.0 %+223.9 %2026Q2
Geode Capital Management4.8 m65.2 m0.0 %+1.2 %2026Q2
Millennium Management3.4 m46.6 m0.0 %-49.2 %2026Q2
Morgan Stanley2.2 m29.8 m0.0 %-33.1 %2026Q2
Northern Trust2.1 m28.2 m0.0 %+8.7 %2026Q2

Latest insider transactions

DatePersonSideAmount
05/08/2026Drinane Juliana Papasale200,307 USD

Elected officials' disclosures

DateOfficialSideAmount
05/08/2026Kevin Hernsale$1,001 - $15,000
05/08/2026Kevin Hernsale$1,001 - $15,000
10/07/2025Gary C. Peterssale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 14/05/2021
ISIN code
US68622V1061
Workforce
10,000
full-time employees
Chief executive
Kevin Ali

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Organon & Co.

What is the Organon & Co. share price?

Latest recorded price: 13.90 USD on 13/11/2026, for a market cap of 3.7 bn USD.

What is the revenue of Organon & Co.?

6.2 bn USD for fiscal year 2025, with net income of 187 m USD (net margin 3.0 %).

What do analysts say about Organon & Co.?

Out of 9 analysts: 2 buy or strong buy, 4 hold, 3 sell or strong sell.

What is the P/E ratio of Organon & Co.?

Trailing 12-month P/E of 4.2, against 27.7 for the sector median on the same exchange (10-year median: 22.3).

Is Organon & Co. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US68622V1061).

How many employees does Organon & Co. have?

10,000 full-time employees according to the latest published profile.

Who runs Organon & Co.?

Kevin Ali is the company's chief executive.

Which large funds own Organon & Co.?

As of 2026Q2, among the large funds tracked: BlackRock, Vanguard Group, State Street, Goldman Sachs, Geode Capital Management.

07

Similar stocks